期刊
DRUG DISCOVERY TODAY
卷 15, 期 23-24, 页码 997-1007出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2010.07.007
关键词
-
资金
- Intramural NIH HHS [Z01 HG200319-04, Z99 HG999999] Funding Source: Medline
The US Tox21 collaborative program represents a paradigm shift in toxicity testing of chemical compounds from traditional in vivo tests to less expensive and higher throughput in vitro methods to prioritize compounds for further study, identify mechanisms of action and ultimately develop predictive models for adverse health effects in humans. The NIH Chemical Genomics Center (NCGC) is an integral component of the Tox21 collaboration owing to its quantitative high-throughput screening (qHTS) paradigm, in which titration-based screening is used to profile hundreds of thousands of compounds per week. Here, we describe the Tox21 collaboration, qHTS-based compound testing and the various Tox21 screening assays that have been validated and tested at the NCGC to date.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据